188 related articles for article (PubMed ID: 9269683)
21. Inhibition of potentially anti-apoptotic proteins by antisense protein kinase C-alpha (Isis 3521) and antisense bcl-2 (G3139) phosphorothioate oligodeoxynucleotides: relationship to the decreased viability of T24 bladder and PC3 prostate cancer cells.
Benimetskaya L; Miller P; Benimetsky S; Maciaszek A; Guga P; Beaucage SL; Wilk A; Grajkowski A; Halperin AL; Stein CA
Mol Pharmacol; 2001 Dec; 60(6):1296-307. PubMed ID: 11723237
[TBL] [Abstract][Full Text] [Related]
22. Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-alpha and C-raf kinase.
Henry SP; Monteith D; Bennett F; Levin AA
Anticancer Drug Des; 1997 Jul; 12(5):409-20. PubMed ID: 9236856
[No Abstract] [Full Text] [Related]
23. Antisense oligonucleotides: an evolving technology for the modulation of gene expression in human disease.
Green DW; Roh H; Pippin J; Drebin JA
J Am Coll Surg; 2000 Jul; 191(1):93-105. PubMed ID: 10898188
[No Abstract] [Full Text] [Related]
24. Bcl-2 antisense therapy in multiple myeloma.
Chanan-Khan AA
Oncology (Williston Park); 2004 Nov; 18(13 Suppl 10):21-4. PubMed ID: 15651173
[TBL] [Abstract][Full Text] [Related]
25. Still looking for the real GEM.
GMHC Treat Issues; 1996 Apr; 10(4):9. PubMed ID: 11363711
[TBL] [Abstract][Full Text] [Related]
26. Targeting the proapoptotic factor Bcl-2 in non-Hodgkin's lymphoma.
Klasa RJ
Oncology (Williston Park); 2004 Nov; 18(13 Suppl 10):25-31. PubMed ID: 15651174
[TBL] [Abstract][Full Text] [Related]
27. British Biotech and MethylGene sign agreement on Phase II antisense drug.
Expert Rev Anticancer Ther; 2002 Feb; 2(1):6. PubMed ID: 12113069
[No Abstract] [Full Text] [Related]
28. GEM 91--an antisense oligonucleotide phosphorothioate as a therapeutic agent for AIDS.
Agrawal S; Tang JY
Antisense Res Dev; 1992; 2(4):261-6. PubMed ID: 1363378
[No Abstract] [Full Text] [Related]
29. Protein kinase C intervention: the state of play.
Roffey J; Rosse C; Linch M; Hibbert A; McDonald NQ; Parker PJ
Curr Opin Cell Biol; 2009 Apr; 21(2):268-79. PubMed ID: 19233632
[TBL] [Abstract][Full Text] [Related]
30. Antisense approaches in drug discovery and development.
Rayburn E; Wang W; Zhang R; Wang H
Prog Drug Res; 2005; 63():227-74. PubMed ID: 16265883
[No Abstract] [Full Text] [Related]
31. Oligonucleotides as inhibitors of human immunodeficiency virus.
Field AK
Curr Opin Mol Ther; 1999 Jun; 1(3):323-31. PubMed ID: 11713797
[TBL] [Abstract][Full Text] [Related]
32. Antisense has growing pains.
Gura T
Science; 1995 Oct; 270(5236):575-7. PubMed ID: 7570012
[No Abstract] [Full Text] [Related]
33. Antisense strategies for oncogene inactivation.
Stein CA; Benimetskaya L; Mani S
Semin Oncol; 2005 Dec; 32(6):563-72. PubMed ID: 16338422
[TBL] [Abstract][Full Text] [Related]
34. Antisense oligonucleotide treatment of inflammatory bowel diseases.
Yacyshyn BR
Methods Mol Med; 2005; 106():295-305. PubMed ID: 15375323
[No Abstract] [Full Text] [Related]
35. Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide.
Yazaki T; Ahmad S; Chahlavi A; Zylber-Katz E; Dean NM; Rabkin SD; Martuza RL; Glazer RI
Mol Pharmacol; 1996 Aug; 50(2):236-42. PubMed ID: 8700129
[TBL] [Abstract][Full Text] [Related]
36. A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer.
Tolcher AW; Reyno L; Venner PM; Ernst SD; Moore M; Geary RS; Chi K; Hall S; Walsh W; Dorr A; Eisenhauer E
Clin Cancer Res; 2002 Aug; 8(8):2530-5. PubMed ID: 12171880
[TBL] [Abstract][Full Text] [Related]
37. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase.
Monia BP; Johnston JF; Geiger T; Muller M; Fabbro D
Nat Med; 1996 Jun; 2(6):668-75. PubMed ID: 8640558
[TBL] [Abstract][Full Text] [Related]
38. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
Zhang C; Pei J; Kumar D; Sakabe I; Boudreau HE; Gokhale PC; Kasid UN
Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711
[TBL] [Abstract][Full Text] [Related]
39. Human Bcl-2 antisense therapy for lymphomas.
Cotter FE; Waters J; Cunningham D
Biochim Biophys Acta; 1999 Dec; 1489(1):97-106. PubMed ID: 10807000
[No Abstract] [Full Text] [Related]
40. Protein kinase C inhibitors.
Swannie HC; Kaye SB
Curr Oncol Rep; 2002 Jan; 4(1):37-46. PubMed ID: 11734112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
